300851-67-6 Usage
General Description
4-Chloro-α-(1-methylethyl)-N-2-thiazolyl-benzeneacetamide, also known as Metolazone, is a chemical compound primarily used in medicine as a diuretic drug. It is part of the thiazide-like diuretic family, and is primarily used to treat congestive heart failure and edema. The key benefit of Metolazone is its ability to still be effective when kidney function is impaired. Metolazone works by blocking the salt and water reabsorption in the kidneys, which subsequently increases urine production. Its chemical formula is C16H16ClN3O3S, and its molecular weight 365.83 g/mol. The compound's systematic name, according to IUPAC, is 7-chloro-1,2,3,4-tetrahydro-2-methyl-3-(2-methylphenyl)-4-oxo-6-quinazolinesulfonamide.
Check Digit Verification of cas no
The CAS Registry Mumber 300851-67-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,0,0,8,5 and 1 respectively; the second part has 2 digits, 6 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 300851-67:
(8*3)+(7*0)+(6*0)+(5*8)+(4*5)+(3*1)+(2*6)+(1*7)=106
106 % 10 = 6
So 300851-67-6 is a valid CAS Registry Number.
300851-67-6Relevant articles and documents
The first synthetic agonists of FFA2: Discovery and SAR of phenylacetamides as allosteric modulators
Wang, Yingcai,Jiao, Xianyun,Kayser, Frank,Liu, Jiwen,Wang, Zhongyu,Wanska, Malgorzata,Greenberg, Joanne,Weiszmann, Jennifer,Ge, Hongfei,Tian, Hui,Wong, Simon,Schwandner, Ralf,Lee, Taeweon,Li, Yang
scheme or table, p. 493 - 498 (2010/04/26)
Free fatty acid receptor 2 (FFA2) is a G-protein coupled receptor for which only short-chain fatty acids (SCFAs) have been reported as endogenous ligands. We describe the discovery and optimization of phenylacetamides as allosteric agonists of FFA2. These novel ligands can suppress adipocyte lipolysis in vitro and reduce plasma FFA levels in vivo, suggesting that these allosteric modulators can serve as pharmacological tools for exploring the potential function of FFA2 in various disease conditions.
